Phase II Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma With Evaluation of Neoadjuvant Biomarker Modulation With TARCEVA vs. TARCEVA Plus Sulindac

Trial Profile

Phase II Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma With Evaluation of Neoadjuvant Biomarker Modulation With TARCEVA vs. TARCEVA Plus Sulindac

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Feb 2016

At a glance

  • Drugs Erlotinib (Primary) ; Sulindac
  • Indications Head and neck cancer
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 May 2014 Planned End Date changed from 1 Jan 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov record.
    • 11 Apr 2014 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top